"Systemic Therapy Outperforms Intraocular Implant For Treating Uveitis"
Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better - and had fewer adverse outcomes - than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute (NEI). "The results of this trial suggest that oral corticosteroids and immunosuppression may be a preferable initial choice for therapy of more severe uveitis," said Douglas A. Jabs, MD, director of the New York Eye and Ear Infirmary of Mount Sinai. "However, the implant may have a role in treating patients where systemic therapy fails to control inflammation or patients cannot tolerate the oral medications."
- Douglas A. Jabs, MD, MBA, Professor, Ophthalmology, Medicine, Icahn School of Medicine at Mount Sinai, Director, Uveitis Division, Mount Sinai Hospital, Director, Mount Sinai/New York Eye and Ear Eye and Vision Research Institute
Blinding Eye Disease Strongly Associated With Serious Forms of Cardiovascular Disease
Nov 17, 2022 View All Press Releases
High-Tech Imaging Offers New Way to Detect Signs of Early Glaucoma
Aug 02, 2022 View All Press Releases
Blinding Eye Disease Is Strongly Associated With Heart Disease and Stroke
Jul 12, 2022 View All Press Releases